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Available online 3 November 2016Background: The physicians often confuse the early symptomsof Frontotemporal dementia (FTD)with Alzheimer
dementia (AD), leading to misdiagnosis. There are some cognitive tests to discriminate between AD and behav-
ioral variant FTD (bvFTD), and the INECO Frontal Screening (IFS) is a promising test for this purpose.
Objective: To assess the performance of the IFS to differentiate patients with AD from patients with bvFTD,
compared with the Frontal Assessment Battery (FAB).
Methods: A prospective study with 117 patients of our cognitive unit (35 case-patients with AD, 34 case-patients
with bvFTD, and 48 control subjects). They were submitted to the following successive phases of evaluation: 1)
screening; 2) dementia diagnosis; and 3) dementia sub-type diagnosis. The IFS and FABwere blind and indepen-
dently applied by one neurologist to all the participants to end of phase 1 (screening), before to the deﬁnitive
diagnosis establishment.
Results: bvFTD showed a lower performance than AD patients on the IFS total score (F(1, 66) = 70.10, p b 0.01)
and FAB total score (F(1, 66) = 17.91, p b 0.01). The IFS and FAB showed a sensitivity of 94.12% (95%CI = 80.3–
99.2) and 82.3% (95%CI = 65.4–93.2), and a speciﬁcity of 94.2% (95%CI = 80.8–99.3) and 48.5% (95%CI = 31.3,
66.1), respectively. The IFS showed signiﬁcantly superior discriminatory accuracy than the FAB (AuCIFS = 0.98;
AuCFAB = 0.73, p b 0.00001).
Conclusion: The IFS is useful for discriminating between AD and bvFTD patients. The performance of the IFS to
differentiate patients with AD from patients with bvFTD is greater than FAB.





Predictive value of tests
Prospective studies1. Introduction
Frontotemporal dementia (FTD) constitutes approximately 2% of all
cases of dementia among people older than 65 years old in Latin
America [1], and it is suspected that would be up to 15% people of
65 years or less [2]. Currently, the physicians are recognizing the late
symptoms of FTD, but its early symptoms may be confused with
Alzheimer dementia (AD) leading to misdiagnosis. Wisconsin Card
Sorting Test (WCST), verbal ﬂuency test (VFT) and Trail Making Testación, Instituto Peruano de
. This is an open access article under(TMT) are useful tools to detect the executive dysfunctions early
showed by patients with FTD [3].
The current diagnostic criteria [4] consider executive functions (EF)
impairments and social cognition problems as key elements for behav-
ioral variant FTD (bvFTD) diagnosis. A neuropsychological assessment is
the gold standard for assessing dementia, but unfortunately it is com-
plex and need highly trained personnel, incurring high costs for health
systems. Thus, in low-income countries it is necessary to assess the
validity of brief cognitive tests developed for discriminating between
dementia and healthy individuals and to properly differentiate between
AD and bvFTD.
Although several cognitive screening tools have desirable diagnostic
and psychometric properties [5], few have been designed to speciﬁcallythe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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easy-to-administer and brief (approximately 10 min) test, which does
not need complex equipment and could be performed at primary care
level. This test was designed to provide health professionals with an
easy to use screening tool to detect frontal impairment in everyday clin-
ical settings or even at bedside. The IFS was designed to include several
subtests in order tomeasure, in an efﬁcientway, asmany EF as possible.
Previous studies have shown promising diagnostic performance [6–10].
Thus, it arises as an encouraging alternative for early detection of
dementia cases.
Previously, we evaluated the performance of Addenbrooke's Cogni-
tive Examination (ACE) in patients with dementia from Peru [11], but
our results showed that it poorly differentiate between AD and bvFTD.
Thereby, the goal of the present study was to assess the clinical useful-
ness of the IFS to differentiate (a) patients with dementia from healthy
controls, and (b) patients with bvFTD from patients with AD and to
compare its performance with the Frontal Assessment Battery (FAB)
[10], another screening test designed to assess executive functions.
2. Materials and methods
2.1. Participants
We designed a prospective study with 117 patients of the Cognitive
ImpairmentDiagnosis andDementia PreventionUnit of the Internation-
al Clinic from Lima, Peru. Using convenience sampling we performed
the recruitment between July 2011 and July 2013. Three groups were
studied: 1) 48 control subjects; 2) 35 case-patients with diagnosis of
probable AD mild-moderate; and 3) 34 case-patients with diagnosis of
probable bvFTD.
For case-patients, we included subjects older than 60 years with de-
mentia diagnosis by DSM-IV criteria [12]. The diagnosis of probable AD
and bvFTD were performed according to NINCDS-ADRDA [13] and
Neary Consensus criteria [14], respectively. Clinical Dementia Rating
Scale (CDR) established the AD stage. This scale was also employed to
the bvFTD patients' assessment. The control group consisted of patients'
relatives or healthy volunteers.
In order to match relevant demographic characteristic among
patients and control groups, control subjects were divided into two
groups. A ﬁrst control group consisted of 23 healthy participants
matched by age, gender and years of education with the AD patients.
The second control group consisted of 25 healthy participants matched
by age, gender and years of education with the bvFTD patients.
We excluded those subjects who were not Spanish native speakers,
participants with low education level (b4 years of education), or with
sensory or physical limitations (visual, auditory, or other physical deﬁ-
cits) that could affect the performance in cognitive tests. Furthermore,
we excluded participants with history of diseases associated with sec-
ondary cognitive impairment (e.g. depression, hypothyroidism, central
nervous system infections such as VIH or syphilis, severe encephalic
traumatism, sub-dural haematoma, deﬁcit of B12 vitamin, chronic
hepatopathy or nephropathy, and addiction or abuse of substances),
as well as subjects with cerebrovascular deﬁcit suspected (score higher
than 4 in the Hachinski index).
All participants providedwritten informed consent. The ethics com-
mittee of the Universidad San Martin de Porres approved the study.
2.2. Procedures
The subjects underwent a standard examination battery including
the following successive evaluations: 1) screening; 2) dementia diagno-
sis; and 3) dementia sub-type diagnosis. In the screening phase, the
evaluators applied the Mini Mental State Examination (MMSE) [15],
the clock drawing test – Mano's version (CDT-Mv) [16] and the Pfeffer
Functional Activities Questionnaire (PFAQ) [17]. Those patients with at
least one positive test for dementia were submitted to the secondevaluation (applied by a second evaluator) with MMSE and CDT-Mv.
For dementia detection with the MMSE, the cut offs were as following:
1) 27 points in subjects higher than 7 years of education; 2) 23 points in
subjects with 4–7 years of education; 3) 22 points in subjects with 1–
3 years of education; and 4) 18 points for illiterate. CDT-Mv and PFAQ
detected cognitive impairment with a score of 0–10 and 0–5, respec-
tively. All cases of cognitive impairment conﬁrmed in second evaluation
were submitted to the next phase.
For dementia diagnosis our protocol included: 1) Beck depression
index (for detection of depressive symptoms) and Addenbrooke's Cog-
nitive Examination; 2) laboratory tests (hemoglobin, glucose, urea, cre-
atinine, aspartate aminotransferase, alanine aminotransferase, albumin,
globulin, vitamin B12, folic acid, VDRL, Elisa VIH, T3, T4 and TSH, and
serum electrolytes such as sodium, potassium and chlorine); and 3)
brain CT scans/MRN. All these testswere applied to investigate the pres-
ence of secondary causes of dementia.
In the last phase, we identiﬁed those patients with probable demen-
tia. The dementia sub-type diagnosis was based on a consensus be-
tween neurologists and neuropsychologist, according to the results of
all diagnostic tests. The neuropsychological battery included the follow-
ing tests: Rey Auditory Verbal Learning Test [18], Logical Memory
Subtest of Weschler Memory Scale - Revised [19], Trail Making Test A
and B [20], Rey-Osterrieth Complex Figure Test [18], Boston Naming
Test [21], Wisconsin Card Sorting Test [22], Letter-Number (subtest of
Weschler Adult Intelligent Scale III) [19], andDigit Span. Neuropsychiat-
ric symptomswere assessed bymeans of the Neuropsychiatric Invento-
ry [23].
All evaluations were done blind and independently by one neurolo-
gist who applied the IFS and FAB to all the participants to end of phase 1
(screening), before to the deﬁnitive diagnosis establishment.
2.3. INECO Frontal Screening (IFS)
The IFS is an screening test to assess executive functions [24], which
includes the following eight subtests: motor programming (3 points);
conﬂicting instructions (3 points); motor inhibitory control (3 points);
backward digit span (6 points); verbal workingmemory (2 points); spa-
tial working memory (4 points); abstraction capacity (3 points); and
verbal inhibitory control (6 points). The IFS has a maximum possible
total score of 30 points and takes b10min to be administered and scored.
2.4. Frontal Assessment Battery (FAB)
The FAB [25] consists of six subtests, which assess conceptualization,
conﬂicting instructions, motor programming, sensitivity to interference,
motor inhibitory control, and prehension behavior. Each subtest is scored
on a maximum of 3 points, rendering a total maximum score of 18.
2.5. Data analysis
All statistical analyses compared the AD patients and bvFTD patients
groups with their respective control groups. Moreover, we compared
the performance of AD and bvFTD patients. The demographic, neuro-
psychological and experimental data were compared between groups
using ANOVA and Tukey's HSD post-hoc tests (when appropriate).
When analyzing categorical variables (gender) chi square test were
applied. Taking the age differences between AD and bvFTD groups
into account, we considered it as covariable in all comparisons between
these two groups. We reported only effects that were still signiﬁcant
after covariation. The p value for all statistical tests was set at 0.05.
In order to compare the usefulness of the IFS and FAB, we determined
the sensitivity and speciﬁcity of each test to discriminate between (a)
healthy controls and patients with dementia, and (b) AD and bvFTD pa-
tients. This was done by means of a receiver-operating characteristic
(ROC) curve, detecting the optimal cut-off scores. The area under the
ROC curve was used as a measure of discriminatory accuracy.
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Descriptive data for demographic and cognitive proﬁles are shown
in Table 1.
3.1. Demographic data
There were no signiﬁcant differences in age between AD patients
and controls (F(1,56) = 1.48, p = 0.22) or bvFTD patients and controls
(F(1,57) = 0.349 p = 0.53). As expected AD were signiﬁcantly older
than bvFTD patients (F(1,67) = 45.93, p b 0.01). No differences in
years of formal educationwere observed between AD patients and con-
trols or bvFTD patients (F(1,56) = 2.30, p = 0.13) and controls
(F(1,57)=2.24p=0.13). Nodifferenceswere observed neither in gen-
der between AD patients and controls (X2(1) = 1.25, p = 0.26) or
bvFTD patients and controls (X2(1) = 2.16, p = 0.14).
3.2. General cognitive state assessment
AD (F(1,56) = 395.20, p b 0.01) and bvFTD patients (F(1,57) =
310.16, p b 0.01) showed lower CDR scores than controls. However,
no differences in CDR scores were observed between AD and bvFTD pa-
tients (F(1,67)= 0.76, p = 0.38). Both AD (F(1,56) = 124.18, p b 0.01)
and bvFTD patients (F(1,57) = 68.42, p b 0.01) exhibited lower MMSE
total scores than controls. Furthermore, AD showed lower performance
than bvFTDpatients in theMMSE (F(1,67)=60.56, p b 0.01).Moreover,
AD (F(1,56)= 461.02, p b 0.01) and bvFTD patients (F(1,57) = 241.42,
p b 0.01) showed a lower performance than controls on the ACE total
score. Furthermore, AD showed lower performance than bvFTDpatients
in the ACE (F(1,67) = 61.58, p b 0.01).
3.3. Executive functions assessment
3.3.1. INECO Frontal Screening (IFS)
3.3.1.1. AD patients vs. controls.ADpatients showed a lower performance
than controls on the IFS total score (F(1, 56) = 199.90, p b 0.01). A de-
tailed comparison of the performance on each of the eight IFS subtests
indicated that AD patients also exhibited a lower performance onTable 1
Demographic and cognitive proﬁles of patients and controls.
AD (n = 35)
mean (SD)
AD controls (n = 23
mean (SD)
Demographics Age (years) 73.57 (3.8) 73.78 (3.3)
Gender (F:M) 19:16 9:14
Education (years) 11.8 (2.8) 10.69 (2.5)
General cognitive state CDR 0.88 (0.21) 0.00 (0.00)
MMSE 21.51 (3.04) 28.78 (0.8)
ACE 67.00 (5.26) 92.34 (5.2)
Executive functions IFS total score 20.02 (2.10) 27.00 (1.3)
Motor series 2.74 (0.44) 2.73 (0.44)
Conﬂictive instructions 1.97 (0.51) 2.86 (0.34)
Motor inhibitory control 1.77 (0.42) 2.13 (0.34)
Digit span 3.6 (0.84) 5.60 (0.58)
Verbal working memory 1.80 (0.40) 2.00 (0.00)
Spatial working memory 2.57 (0.55) 3.60 (0.49)
Abstraction capacity 2.00 (0.42) 2.82 (0.38)
Verbal inhibitory control 3.57 (0.50) 5.21 (0.59)
FAB total score 13.54 (1.78) 16.39 (0.8)
Verbal ﬂuency 2.11 (0.58) 2.82 (0.38)
Conceptualization 2.28 (0.66) 2.95 (0.20)
Prehension behavior 2.65 (0.48) 2.91 (0.28)
Phonological ﬂuency 7.94 (2.07) 19.27 (1.5)
TMT-B 181 (28.8) 55.17 (9.0)
WCST categories 2.97 (0.56) 5.17 (0.38)
WCST errors 6.68 (1.62) 0.86 (0.69)
Signiﬁcant differences between groups are indicated in bold. CDR= Clinical Dementia Rating,M
IFS = INECO Frontal Screening, FAB = Frontal Assessment Battery, TMT-B = Trail Making Tessubtests of conﬂictive instructions (F(1, 56) = 54.14, p b 0.01), motor
inhibitory control (F(1, 56) = 11.40, p b 0.01), digit backward span
(F(1, 56) = 98.37, p b 0.01), verbal working memory (F(1, 56) =
5.55, p b 0.05), spatial working memory (F(1, 56) = 52.10, p b 0.01),
abstraction capacity (F(1, 56) = 57.00, p b 0.01) and verbal inhibitory
control (F(1, 56) = 127.74, p b 0.01).
3.3.1.2. bvFTD patients vs. controls. bvFTD patients also showed a lower
performance than controls on the IFS total score (F(1, 57) = 746.0,
p b 0.01). A detailed comparison of the performance on each of the
eight IFS subtests indicated that bvFTD patients exhibited a lower
performance on subtests of motor programming (F(1, 57) = 64.76,
p b 0.01), motor inhibitory control (F(1, 57) = 119.85, p b 0.01), digit
backward span (F(1, 57) = 208.99, p b 0.01), verbal working memory
(F(1, 57) = 104.10, p b 0.01), spatial working memory (F(1, 57) =
69.80, p b 0.01), abstraction capacity (F(1, 57) = 106.58, p b 0.01) and
verbal inhibitory control (F(1, 57) = 445.36, p b 0.01).
3.3.1.3. AD vs. bvFTD patients. bvFTD showed a lower performance than
AD patients on the IFS total score (F(1, 66)=70.10, p b 0.01). A detailed
comparison of the performance on each of the eight IFS subtests indicat-
ed that bvFTD patients exhibited a lower performance on the motor
programming subtest (F(1, 66) = 47.58, p b 0.01), though a signiﬁcant
effect of age was observed (p= 0.04). AD performedworse than bvFTD
patients on the conﬂictive instructions subtest (F(1, 66) = 18.79,
p b 0.01). However, bvFTD showed lower scores than AD patients on
motor inhibitory control (F(1,66) = 61.28, p b 0.01), verbal working
memory (F(1,66) = 43.60, p b 0.01), abstraction capacity (F(1,66) =
36.17, p b 0.01) and verbal inhibitory control (F(1, 66) = 151.94,
p b 0.01).
3.3.2. Frontal Assessment Battery (FAB)
3.3.2.1. AD patients vs. controls.ADpatients showed a lower performance
than controls on the FAB total score (F(1, 56)= 49.98, p b 0.01). A com-
parison of the performance on the subtests unique to the FAB indicated
that AD patients exhibited a lower performance on conceptualization
(F(1, 56) = 21.72, p b 0.01), verbal ﬂuency (F(1, 56) = 26.52,
p b 0.01), and prehension behavior (F(1, 56) = 5.24, p b 0.05).) AD vs. CTR FTD (n = 34)
mean (SD)
FTD vs. CTR FTD controls (n = 25)
mean (SD)
AD vs. FTD
0.22 67.08 (4.04) 0.53 66.52 (2.4) b0.01
0.26 18:16 0.14 18:7 0.91
0.13 11.73 (2.66) 0.13 12.8 (2.3) 0.92
b0.01 0.83 (0.23) b0.01 0.00 (0.00) 0.38
b0.01 26.11 (1.64) b0.01 29.04 (0.3) b0.01
b0.01 76.61 (4.90) b0.01 93.40 (2.6) b0.01
b0.01 14.55 (2.16) b0.01 27.04 (0.8) b0.01
0.97 2.02 (0.38) b0.01 2.84 (0.37) b0.01
b0.01 2.61 (0.55) 0.16 2.80 (0.40) b0.01
b0.01 0.73 (0.66) b0.01 2.48 (0.50) b0.01
b0.01 3.32 (0.58) b0.01 5.44 (0.50) 0.12
b0.01 0.73 (0.61) b0.01 2.00 (0.00) b0.01
b0.01 2.70 (0.46) b0.01 3.72 (0.45) 0.28
b0.01 1.14 (0.55) b0.01 2.60 (0.50) b0.01
b0.01 1.26 (0.66) b0.01 5.16 (0.74) b0.01
b0.01 11.97 (1.52) b0.01 16.52 (0.9) b0.01
b0.01 2.32 (0.72) 0.10 2.60 (0.50) 0.19
b0.01 1.88 (0.47) b0.01 2.88 (0.33) b0.01
b0.01 2.26 (0.44) b0.01 2.88 (0.33) b0.01
b0.01 7.79 (2.54) b0.01 20.88 (2.5) 0.79
b0.01 205.73 (38.7) b0.01 58.8 (10.4) b0.01
b0.01 2.44 (0.89) b0.01 5.24 (0.43) 0.06
b0.01 12.32 (2.96) b0.01 0.88 (0.60) b0.01
MSE=Mini Mental State Examination, ACE = Addenbrook's Cognitive Examination,
t B, WCST =Wisconsin Card Sorting Test.
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performance than controls on the FAB total score (F(1, 57) = 171.31,
p b 0.01). A detailed comparison of the performance on the subtests
unique to the FAB indicated that bvFTD patients exhibited a lower per-
formance on conceptualization (F(1, 57)=80.37, p b 0.01) and prehen-
sion behavior (F(1, 57) = 33.58, p b 0.01).
3.3.2.3. AD vs. bvFTD patients. bvFTD showed a lower performance than
AD patients on the FAB total score (F(1, 66) = 17.91, p b 0.01). A de-
tailed comparison of the performance on the subtests unique to the
FAB showed that bvFTD patients exhibited a lower performance than
AD patients on the conceptualization (F(1,66)=6.70, p b 0.05) and pre-
hension behavior (F(1, 66) = 6.29, p b 0.05) subtests.
3.3.3. Other executive functions measures
3.3.3.1. AD patients vs. controls.ADpatients showed a lower performance
than controls on phonological ﬂuency (F(1, 56)= 523.34, p b 0.01), the
TMT-B test (F(1, 56) = 409.10, p b 0.01), the number of categories
achieved (F(1, 56) = 264.11, p b 0.01) and the number of errors made
on the WCST (F(1, 56) = 262.52, p b 0.01).
3.3.3.2. bvFTD patients vs. controls. bvFTD patients also showed a lower
performance than controls on phonological ﬂuency (F(1, 57) =
384.00, p b 0.01), the TMT-B test (F(1,57)= 340.69, p b 0.01), the num-
ber of categories achieved (F(1, 57)=207.89, p b 0.01) and the number
of errors made on the WCST (F(1, 57) = 360.77, p b 0.01).
3.3.3.3. AD vs. bvFTDpatients. Compared to AD, bvFTDpatients tookmore
time to complete the TMT-B (F(1,66)=16.29, p b 0.01) andmademore
preservative errors on the WCST (F(1, 66) = 68.05, p b 0.01).
3.4. Receiver operating characteristic (ROC) curve analyses
A cutoff score of 23.5 points (out of 30) on the IFS was associated
with a sensitivity of 97.1%, 95% conﬁdence interval (95%CI) = [89.9,
99.9], and a speciﬁcity of 97.9%, 95%CI = [88.9, 99.9], for the detection
of dementia (AD and bvFTD). Regarding the FAB, a cut-off score of
14.5 (out of 18) showed a speciﬁcity of 81.1%, 95%CI = [69.9, 89.5]
and a sensitivity of 97.9%, 95%CI = [88.3, 99.9]. As shown by Fig. 1, the
discriminatory accuracy (patients with dementia vs. healthy controls)
of the IFS (AuC = 0.99, SE = 0.001) was superior to that of the FAB
(AuC= 0.95, SE=0.01), and this difference was statistically signiﬁcant
(z= 1.84, p b 0.05).
In comparing the capacity to discriminate between types of demen-
tia (AD vs. bvFTD), the IFS showed a sensitivity of 94.12%, 95%CI= [80.3,
99.2] and speciﬁcity of 94.2%, 95%CI = [80.8, 99.3], using a cut-off score
of 17.5 points. On the contrary, a 13-point cut-off score on the FAB
showed a sensitivity of 82.3%, 95%CI= [65.4, 93.2], but a low speciﬁcity
of 48.5%, 95%CI = [31.3, 66.1]. Again, the IFS showed superiorFig. 1. ROC curve for the discrimination between dementia patients and healthy control
subjects by IFS and FAB tests.discriminatory accuracy (AuC = 0.98, SE = 0.009) than the FAB
(AuC= 0.73, SE=0.05), and this difference was statistically signiﬁcant
(z= 5.57, p b 0.00001), as revealed by Fig. 2.
4. Discussion
The goal of this study was to assess the clinical usefulness of the IFS
to differentiate (a) patients with dementia from healthy controls, and
(b) patientswith bvFTD frompatientswith AD.Moreover, we compared
the performance of the IFSwith that of the FAB. Our results showed that
the IFS have a good sensitivity and speciﬁcity to discriminate between
patients with dementia and healthy controls, and between AD and
bvFTDpatients. Furthermore,we found that thediscrimination accuracy
of the IFS is higher than that of the FAB. These ﬁndings are consistent
with those previously reported by other researchers [6,10,26,27].
Speciﬁcally, our results support those of a previous study carried out
in Argentina [6] showing that the IFS accurately discriminate between
demented patients and healthy controls as well as between AD and
bvFTD patients. Moreover, the present results agree with those of a pre-
vious study [10] reporting that, relative to the FAB, the IFS showed bet-
ter capability to differentiate between AD and bvFTD. Finally, our
ﬁndings suggest that although the FABmay be useful for discriminating
between patients with dementia and healthy individuals, this screening
test has a low speciﬁcity for discriminating between AD and bvFTD pa-
tients. Even though some studies [28–30] have shown that the FABmay
be useful to discriminate between AD and bvFTD, our results did not
support this observation. Instead of this, our ﬁndings are consistent
with previous evidence [26,27] suggesting that the FAB does not accu-
rately differentiate AD from bvFTD patients.
Additionally, based on the analysis of the performance on IFS sub-
tests, our ﬁndings suggest that the conﬂictive instructions subtest
would be the most accurate for AD detection and subtests of verbal
working memory, abstraction capacity and verbal inhibitory control
would be themost accurate for bvFTD detection. Theseﬁndings are con-
sistent with those a previous study using the same screening tools [10].
In comparison with other brief tests assessing the general cognitive
state such asMMSE and ACE, executive dysfunctionwas better detected
with both IFS and FAB tests [6,25,32–34]. Thus, patients with bvFTD
have lower scores than AD patients in these tests, while patients with
AD have lower scores than patients with bvFTD in the general cognitive
screening tests such as MMSE and ACE. Based on these ﬁndings, we be-
lieve that both MMSE and ACE may not be the best option in patients
with bvFTD because those tests are not efﬁcient for assessing the
dysexecutive changes frequently observed in frontal pathologies. Thus,
MMSE and ACE could not detect early cases of bvFTD.
Curiously, in applying the MMSE and ACE testing we have shown
that patientswith bvFTD showedperformances in the domains ofmem-
ory and reasoning similar to those of patientswithAD, despite the youn-
ger age of patients with bvFTD. This ﬁnding has been previously
reported [35]. Finally, our study showed that other executive functionsFig. 2. ROC curve for the discrimination between AD patients and FD patients by IFS and
FAB tests.
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could be interesting tools to differentiate between patients with
bvFTD, AD, and healthy individuals.
This study has some limitations. First, our sample was relatively
small. Thus, the future research should include larger sample sizes
with patients with multiple dementia sub-types to approximate a
more realistic scenario. Second, the comparison groups were homoge-
neous in years of education. Future studies should evaluate whether
the results are consistent across groups with different educational
levels.
However, the importance of our study lies in three points. First, in
low-income countries is necessary to dispose of validated brief cogni-
tive tests for discriminating between dementia of healthy individuals
and, simultaneously, it to discriminate between dementia subtypes.
For example, in Peru the only validated cognitive tests for screening de-
mentia are MMSE, PDR-M, T@M and ACE. Second, the dysexecutive
manifestations of behavioral variant bvFTD [36] can only be detected
by the use of complex tests requiring trained personnel for its enforce-
ment, such as phonological ﬂuency, TMT-B test, and WCST [37]. Tests
with these properties are Mini SEA [38], FAB and IFS [10].
In conclusion, the IFS is a test with a good performance for screening
executive functions in patients with dementia. Moreover, the IFS is use-
ful in discriminating between AD and bvFTD patients. We recommend
the inclusion of the IFS screening test in screening protocols for demen-
tia for the early detection of bvFTD.
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